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scribing to children and adults in a primary care patient population. METHODS: A
retrospective, cross-sectional pharmacoepidemiological study was conducted on
data of a national community pharmacy group in South Africa for 2010. All records
for methylphenidate and/or atomoxetine (ATC Code N06BA) were analysed. Pa-
tients under 18 years were labeled as children, and patients over 18 years as adults.
RESULTS: A total of 22 387 patients (70.05% children and 29.95% adults) received
one or more prescriptions for methylphenidate and/or atomoxetine during 2010. A
total of 60 370 prescriptions were dispensed (75.54% to children and 24.46% to
adults). Most adult patients (43.11%) were between 19 and 29 years of age. Nearly
three-quarters of children (71.84%) were males, compared to only 55.32% of adults.
Children received on average 2.91 prescriptions during the year and adults only
2.20. Methylphenidate accounted for 90.00% of prescriptions to children, and
94.60% to adults. The average sales value for a methylphenidate prescription was
R366.13 for children and R408.42 for adults, compared to the average cost for an
atomoxetine prescription of R582.31 for children and R653.94 for adults. There is no
generic equivalent available for atomoxetine on the South African market. The
average Prescribed Daily Dose (PDD) for methylphenidate was estimated to be 26.27
(SD15.27) mg for children and 41.86 (SD98.57) mg for adults, and the average
PDD for atomoxetine was 38.70 (SD21.45) mg for children and 65.96 (SD118.67)
mg for adults. No seasonal variation was observed for atomoxetine, but methyl-
phenidate prescribing showed peaks and troughs corresponding with the June/July
and December/January holiday periods. CONCLUSIONS: The duration of treatment
and complexity of ADHD treatment is growing, extending into adulthood. Compre-
hensive cost studies into adult ADHD are needed that include quality-of-life and
productivity factors.
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Onishi Y1, Hinotsu S1, Furukawa TA2, Kawakami K1
1Kyoto University, Kyoto, Japan, 2Kyoto University, kyoto, Kyoto-fu, Japan
OBJECTIVES: Clinical guidelines recommend monotherapy with antidepressants
for major depression. This study examined prescription patterns and trends as well
as antidepressant polypharmacy among patients with major depression based on
the claims database of health insurance societies between 2008 and 2011 in Japan.
METHODS: Retrospective cohort (N750,000) followed up for four years was used
to identify patients (age  18) with newly diagnosed non-psychotic major depres-
sion. The prescription patterns were examined for antidepressants (first and sec-
ond generation), BZD anxiolytics and hypnotics, sulpiride, and antipsycotics. The
data were analyzed by intent-to-treat approach at month 0, 3, 6 and 12 from the
date of diagnosis. RESULTS: A total of 10,967 patients (male: 5,362, mean age:
3711) with major depression were identified. The proportion of patients pre-
scribed at least one medication was 84% (month 0), 41% (month 3), 35% (month 6)
and 23% (month12). The proportion of patients prescribed antidepressant was 56%
(month 0), 29% (month 3), 24% (month 6) and 16% (month12). BZD anxiolytic was
prescribed to 56% (month 0), 26% (month 3), 22% (month 6) and 14% (month 12) of
the cohort. BZD hypnotics were prescribed to 25% of patients at month 0. Sulpiride
was prescribed to 25%. The proportion of patients with monotherapy of antidepres-
sant was 12% (month 0). Various combinations of polypharmacy were observed.
The most common was combination of antidepressant and BZD anxiolytics (20% at
month 0). Antidepressant with both BDZ anxiolytics and BDZ hypnotics (8% at
month 0) as well as the combination of sulpiride and BZD anxiolytics (6% at month
0) were also common. CONCLUSIONS: The majority of patterns and trends of an-
tidepressant treatment did not follow the guideline recommendation. Various pat-
terns of prescriptions and polypharmacy were observed over time.
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OBJECTIVES: The buprenorphine/naloxone combination has been available in a
film formulation for the treatment of opioid dependence since 2010. A clinical trial
showed that patients preferred the film to tablet formulation. Insurance claims
data were analysed to compare patient persistence with the two formulations.
METHODS: A retrospective cohort analysis was performed using medical insur-
ance claim records extracted from the Invision Datamart database. Previously un-
treated patients who initiated treatment with buprenorphine/naloxone following
the launch of film were classified in two groups according to formulation of initial
prescription. Persistence was defined as the proportion of patients continuing
treatment for at least 6 months, with possible change in formulation. RESULTS:
The film and tablet groups included 1095 and 1048 patients respectively, enrolled
over 6.45 and 8.68 months from initiation of buprenorphine/naloxone on average.
Patient characteristics were similar between groups. In the tablet group, 12.40% of
patients switched to film after 44.5 days on average. Of the patients on film, 2.74%
switched to tablet. Mean prescribed doses were 15.37 and 14.33 mg/day in film and
tablet groups. Among patients enrolled for at least 6 months from buprenorphine/
naloxone initiation, persistence rates were 63.02% in film group vs. 57.97% with
tablet. The time to treatment discontinuation was longer in the film group, with a
hazard ratio of 0.754 (p0.0002) adjusted on age, gender, region, health plan cate-
gory, co-payment proportion, and dose. CONCLUSIONS: Patients started on bu-
prenorphine/naloxone film formulation are more likely to stay on treatment than
patients treated with tablet formulation.
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OBJECTIVES: The discussion on compliance versus non-compliance exercises
many minds in ADHD. Given the potential economic impact, we investigated soci-
etal costs among compliant and non-compliant children with ADHD.METHODS: A
cross-sectional retrospective survey among parents of a child aged 6-18 (members
of the Dutch patient organization) with ADHD was conducted in September 2010.
The TiC-P questionnaire was used to collect data on medical and non-medical
resource use. Reference prices (2010) from the Netherlands were taken as unit
costs. Differences were analysed using Students’ t-tests. Compliance status was
based on parent evaluation and based on pre-defined definitions supported by
expert opinion. RESULTS: This first analysis was based on 473 and 219 children
who were compliant or non-compliant to pharmacological treatment, respectively.
Mean age was 11.2 years, 82.8% were boys. Compliance had a significant influence
on total treatment costs, with total mean monthly costs being €543 (SD € 1141) and
€879 (SD €1368) for compliant and non-compliant children, respectively (p0.001).
The most important cost items were medical consultations (23.4% vs. 26.3%),
coaching and extra support lessons at school (24.0% vs. 18.5%), skills trainings
(18.2% vs. 19.0%), and child day care (13.8% vs. 11.0%). Medication constituted 4.8%
and 2.7% of total costs. Next to compliance, regression analysis showed that co-
morbidity also had a significant influence on total treatment costs (p0.000). In a
regression model in which compliance and comorbidity were independent vari-
ables, both were significant (p0.003 and p0.000, respectively). Mean costs were
€253 and €659 (compliant vs. non-compliant) for children without comorbidity and
€669 and €950 for children with comorbidity. Adding a dummy for
comorbidity*compliance did not show a significant interaction between the two.
CONCLUSIONS: Children compliant to ADHD medication have significant lower
monthly costs compared to non-compliant children. So, effective methods to im-
prove compliance medication in this patient population may be cost-effective.
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OBJECTIVES: Due to varying survey methods and samples, annual direct cost esti-
mates for the care of major depression (MD) in Germany vary between 1264€ and
2577€ per patient in bottom-up cost analyses. To obtain more precise estimates for
costs of MD, we drew a sample from claims data of a statutory health insurance
covering approx. 11% of the German population. By accounting for levels of disease
severity and comorbidities, we (a) provide a stratified cost analysis for MD in Ger-
many and (b) explore potential bias caused by small samples or population selec-
tion criteria. METHODS: We selected a patient cohort aged 18 to 65 and not treated
for depression in the previous 6 months with (a) at least two secured diagnoses of
depression in 2010 and (b) the first depression-related service utilization between
01.01.2010 and 15.02.2010. Depression-related costs for outpatient-care, inpatient-
care, and antidepressants were analyzed for the remaining year 2010 in total and
by provider. Patients were stratified into three disease severity (ds) levels: minor/
unspecified/atypical (ds1), moderate (ds2), and severe (ds3) MD. Furthermore 128
(co)morbidity groups were analyzed. RESULTS: The sample comprised 18,139 pa-
tients with a mean of 887€ in annual direct costs for care of MD. Mean costs by
disease severity and mental comorbidity (mc) were for (ds1): n 11,978 (66%), 623€
(without/with mc 509€/737€); for (ds2): n  4,420 (24%), 1231€ (without/with mc
1056€/1601€); for (ds3): n 1741 (10%), 1838€ (without/with mc 1389€/2483€). While
mental comorbidities significantly explained higher direct costs for depression for
every provider, somatic comorbidities did not. CONCLUSIONS: Our sample re-
vealed (a) a large proportion of patients with low disease severity (ds1) and (b) large
cost differences explained by disease severity and mental comorbidities. Compa-
rable studies reporting higher mean costs for depression may possibly underrep-
resent patients with low disease severity in their sample.
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LONGITUDINAL ANALYSIS OF PATIENT LEVEL HEALTH CARE COSTS IN
PATIENTS WITH MAJOR DEPRESSIVE DISORDER TREATED WITH DULOXETINE
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OBJECTIVES: To develop and apply a longitudinal model adjusting for pre-treat-
ment covariates to examine trajectory patterns of health care costs in patients with
major depressive disorder (MDD) treated with duloxetine. METHODS: Retrospec-
tive health care cost data from Thomson Reuters MarketScan® Database for 10,987
MDD patients, aged 18-64 initiating duloxetine in 2007 at low, standard, or high
doses (60, 60, or 60 mg/day) were used to build a longitudinal model for the
A335V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) A 2 7 7 – A 5 7 5
examination of trajectory patterns of patient-level health care costs. The model
was adjusted for baseline demographics, Charlson comorbidity index (CCI), body
system index (BSI), and prior medication index (PMI). Rates of change (slopes) were
estimated from the fitted model and differences in the cost trajectory patterns
among dosing cohorts were tested using F-test. Bootstrapping was used to provide
a sensitivity analysis. RESULTS: A repeated measures linear mixed model with
dose, month, and dose*month as fixed effects and patient, patient*dose as a ran-
dom effects, adjusting for demographics, CCI, BSI, and PMI, was developed. Main
effects and covariates were all significant (all p.05). The model revealed that total
health care costs increased sharply in the months leading up to, and decreased in
the months following, initiation of duloxetine treatment for each dosing cohort
and the overall cohort (all p.05). Compared to patients given low- or standard-
dose therapy, patients who received high-dose duloxetine had higher health care
expenses both prior to and following initiation of duloxetine therapy (p.05). Boot-
strapping confirmed the above test results. CONCLUSIONS: Longitudinal models
provide great opportunities to assess changes in cost trajectory patterns around the time
ofchanges inmedical treatmentcomparedtothecurrentstandardmeanmethods. Inthis
analysis, health care costs increased prior to the initiation of duloxetine therapy, perhaps
signaling a clinical deterioration that led to a change in treatment strategy. Health care
costs then decreased following initiation of duloxetine treatment.
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OBJECTIVES: To evaluate the health care and productivity costs in patients with
generalized anxiety disorder (GAD) before and after the initiation of a SSRI
(selective serotonin re-uptake inhibitor), a SNRI (serotonin norepinephrine re-
uptake inhibitor), benzodiazepine or pregabalin. METHODS: Patients with an
ICD10-code F40-F41 and at least two prescription claims for either SSRI, SNRI,
benzodiazepin or pregabalin were identified using data from the Danish Na-
tional Patient Registry, the Psychiatric Central Registry, the Medicinal Registry
and other registries (2006-2010). Patients identified with neuropathic pain were
excluded. The index date was considered the first prescription for SSRI, SNRI,
benzodiazepines or pregabalin. Descriptive assessments of health care and pro-
ductivity costs were conducted 12 months pre and post the index date using the
full dataset, whereas a sub-analysis focussed on F41.1 (GAD). To control for
selection bias, a propensity score matched cohort controlling for age, gender,
Charlson score, depression, alcoholism, socioeconomic and cohabit status, and
health care resource use was also conducted. Statistical tests performed were
Wilcoxon (0.05). RESULTS: A total of 18,357 (F40-F41) patients met the inclu-
sion criteria (treatment courses included: 14,095 SSRI; 5,035 SNRI; 8,580 benzo-
diazepines; 1,628 pregabalin). Twelve months health care costs were only sig-
nificantly reduced in the pregabalin group (€1,285; P0.001). The three other
groups resulted in significantly increased health care costs (€808-€1,548;
P0.001). Similar results were found focusing only on F41.1; however insignifi-
cant for pregabalin. Matched sub-analyses covering 1,588 patients in each group
showed similar significant reduced 12 months health care costs in the SNRI and
pregabalin groups (P0.001). Across all four groups the ability to retain employ-
ment was significantly improved, whereas long-term sickness increased; how-
ever, insignificantly so in the pregabalin group. CONCLUSIONS: Health care
costs 12 months after the initiation of the treatment with pregabalin were sig-
nificantly reduced. Besides pregabalin, this was in matched analyses also the
case for the SNRI group. Production loss did not differ between groups.
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OBJECTIVES: A 2005 systematic review identified no cost-effectiveness studies
in paediatric bipolar disorder (PBD). Following a recent surge in clinical research
on the use of atypical antipsychotics in this area, an update of the review is
necessary to inform economic models. The current systematic review objective
was to identify all literature published since 2005 on economic aspects of PBD.
METHODS: EMBASE, MEDLINE, PsychINFO, CINAHL, EconLIT, and NHSEED were
systematically searched from 2005 to January 2012. Articles were included if
they reported an economic evaluation (cost-minimisation, cost-effectiveness,
cost-utility or cost-benefit study), details of costs of care, resource use, health-
related quality of life (HRQoL) or utilities for patients aged 18 years with bipo-
lar disorder. No limits were put on language or country. Full texts of potentially
relevant articles were obtained and assessed against the same inclusion crite-
ria. Reference lists and congress abstracts were also searched. RESULTS:Of 5388
search results, 104 were deemed potentially relevant. After review of full texts,
5 studies were included that reported HRQoL data for bipolar patients 18yrs.
No articles were found that reported on economic evaluations, costs of care,
resource use or utilities for PBD. Two congress abstracts reported PQ-LES-Q
values from an aripiprazole RCT and 1 reported CHQ-PF50 from a quetiapine
RCT. Both treatments were found to improve HRQoL, but the difference from
placebo did not reach significance for aripiprazole over the 4 week trial. Other
studies found that PBD was associated with significantly lower HRQoL than
other common childhood conditions and that HRQoL might be more affected by
depressive than manic symptoms. CONCLUSIONS: Despite the increase in the
number of clinical trials on treatments for paediatric bipolar disorder, there are
currently no published cost-effectiveness studies, cost/resource use data or
utilities. These data will be required to inform reliable cost-effectiveness mod-
els of treatments in this field.
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OBJECTIVES: In Germany, about 500,000 people suffer from Schizophrenia. Due to
its chronic relapsing course that involves fundamental functional and social im-
pairment, schizophrenia has emerged as a dominant burden to society. However,
studies to determine the economic consequences of the disease have largely been
carried out in clinical settings based on a relatively small number of cases. There-
fore we aim to assess the medical and non-medical consequences of schizophrenia
as well as the cost structure across treatment settings and population characteris-
tics using administrative data. METHODS: Costs attributable to Schizophrenia
were estimated using a case-control design, where 26,294 patients drawn from a
sickness fund administrative database were matched to 9,319 patients with a con-
firmed diagnosis of schizophrenia (ICD-10: F20). To obtain balance between both
groups in a set of observed pre-treatment variables (age, sex, prior number of drug
prescriptions, Elixhauser comorbidities) and to reduce the conditional bias, a ge-
netic matching algorithm was employed. Eventually, costs and other health care
resource utilization parameters for cases and controls were recorded during 2008.
RESULTS: The annual cost attributable to Schizophrenia amounts to € 10610 per
patient from the payer’s perspective, and € 19927 from the societal perspective.
Lost productivity (46.6%), inpatient treatment (29.0%) and nursing care (14.3%) are
the major cost drivers of the disease. The burden of disease of Schizophrenia in
Germany is estimated to be approximately € 5220 million per year from the sick-
ness fund perspective and € 9804 million from the societal perspective.
CONCLUSIONS: While our calculations still underestimate the true burden of dis-
ease due to restricting quality of life to production forgone and due to ignoring the
impact on family members, considerable direct and indirect costs of schizophrenia
highlight the need for further research in order to improve care patterns and to find
innovate treatment solutions.
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OBJECTIVES: Schizophrenia places a heavy burden on individuals and their care-
givers, as well as potentially placing a large demand on the health care system and
its resources. The objective was to understand the cost burden imposed by schizo-
phrenia, and to identify the key drivers of costs. METHODS: We conducted a liter-
ature review capturing reviews and recent individual studies on costs of the dis-
ease in Europe and US, using Embase and Medline databases. RESULTS: Thirty-six
references were included, covering 8 countries (UK, France, Germany, Norway,
Canada, US, India and Thailand). Costs described were mainly those related to care
settings (hospital or community), pharmacological and non pharmacological ther-
apies, comorbidities and family or caregiver costs. The absolute costs were variable
across studies (e.g. from €5,000 to €12,000 per year in England, from $8,000 to
$26,000 per year in Canada and from 86,000THB to 146,000 THB in Thailand). This
was due primarily to the differences in the national health care system, but also to
the type of costs included in the analyses. Key drivers of costs included gender
(male patients were about 50% more costly), type of medication, and previous
psychiatric hospital admission. Costs also increased with severity of the disease.
CONCLUSIONS: The burden of schizophrenia is significant regardless of the coun-
try; however variable estimates of the burden are available in literature due mainly
to the treatment regimens used and the approaches to schizophrenia care (e.g.
hospital based versus community-based) in respective countries. At present, there
is a need of a standard method for quantitatively assessing and aggregating the
various aspects of the cost of schizophrenia.
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OBJECTIVES: Schizophrenia is a chronic and disabling severe mental disorder
with considerable economic importance. Detailed estimates of treatment pat-
terns and costs of outpatient and inpatient treatment of patients with schizo-
phrenia are an important input factor for health economic cost-effectiveness
models. Up to date there are several publications which assess the treatment
patterns and costs of schizophrenia in Germany. However, most of the infor-
mation is limited as an input for cost-effectiveness models due to the fact that
differentiated micro information about the frequency of contacts in different
treatment areas and costs of a single contact are missing. Therefore, we exam-
ine the treatment patterns and micro costs of treatment of schizophrenia re-
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